Literature DB >> 15955174

A new concept of accommodation in ABO-incompatible kidney transplantation.

Kota Takahashi1.   

Abstract

This work focuses on the mechanism of acute antibody-mediated rejection leading to graft loss and the mechanisms of accommodation permitting graft survival in ABO-incompatible kidney transplantation. As previously noted, accommodation occurs only with (i) post-transplant suppression of glycosyltransferase, a product of ABO histo-blood group genes in the graft and (ii) prevention of antigen-antibody reactions and delayed hyperacute rejection due to reduced antigenicity of enzyme-regulated histo-blood group antigens. This article discusses the mechanism of ABO histo-blood group glycosyltransferase suppression. Accommodation is always established in successful ABO-incompatible organ grafts and ABO-minor mismatch bone marrow transplantation. In the former, accommodation develops even though ABO histo-blood types of the recipient and the donor are incompatible. In the latter, infusion of donor-derived bone marrow causes the recipient's blood to be eventually replaced by blood of the donor's type. However, the recipient's organs retain their original tissue type. In successful bone marrow engraftment, accommodation is established regardless of ABO-incompatibility. In organ transplantation the recipient's ABO histo-blood type regulates the graft's ABO histo-blood type, while in bone marrow transplantation the new ABO histo-blood type from the donor suppresses and regulates the ABO histo-blood type in recipient organs. In other words, bone marrow-derived histo-blood type regulates the histo-blood type of the organs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955174     DOI: 10.1111/j.1399-0012.2005.00392.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  7 in total

1.  Correlation between insulin requirements and anti-galactose antibodies in patients with type 1 diabetes transplanted with neonatal pig islets.

Authors:  R Esquivel-Pérez; A L Rodriguez-Ventura; L M Dorantes; B Ramírez-González; M G López-Santos; R Valdes-Gonzalez
Journal:  Clin Exp Immunol       Date:  2011-04-19       Impact factor: 4.330

Review 2.  Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation.

Authors:  Kota Takahashi
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

3.  Short-term results of ABO-incompatible living donor kidney transplantation: comparison with ABO-compatible grafts.

Authors:  Jeong Kye Hwang; Sang Il Kim; Bum Soon Choi; Cheol Woo Yang; Yong Soo Kim; In Sung Moon; Ji Il Kim
Journal:  J Korean Surg Soc       Date:  2011-07-11

4.  ABO Incompatible Kidney Transplantation-Current Status and Uncertainties.

Authors:  Milljae Shin; Sung-Joo Kim
Journal:  J Transplant       Date:  2011-12-10

5.  Unexpected immunoresponse to Gal and APA antigens in diabetic type 1 patients receiving neonatal pig islets after 6 years.

Authors:  Rafael A Valdés-González; Luis M Dorantes; G Nayely Garibay; Eduardo Bracho-Blanchet; Roberto Dávila-Pérez; Luis Terán; Christopher E Ormsby; Jorge-Tonatiuh Ayala-Sumuano; Laura Copeman; David J G White
Journal:  J Clin Immunol       Date:  2007-03-15       Impact factor: 8.542

6.  Effects of Neutralization by Soluble ABH Antigens Produced by Transplanted Kidneys From ABO-Incompatible Secretor Donors.

Authors:  Jieun Kim; Sinyoung Kim; In Sik Hwang; Jong Rak Choi; Jae Geun Lee; Yu Seun Kim; Myoung Soo Kim; Hyun Ok Kim
Journal:  Ann Lab Med       Date:  2017-05       Impact factor: 3.464

7.  Complement activation and long-term graft function in ABO-incompatible kidney transplantation.

Authors:  Marit S van Sandwijk; Astrid Klooster; Ineke Jm Ten Berge; Arjan Diepstra; Sandrine Florquin; Joris J Hoelbeek; Frederike J Bemelman; Jan-Stephan Sanders
Journal:  World J Nephrol       Date:  2019-10-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.